文献速递区域麻醉与超声疼痛医学

全膝关节置换术中局部浸润镇痛后罗哌卡因血药浓度:固定剂量给药安全性的药代动力学研究

Plasma Ropivacaine Concentrations Following Local Infiltration Analgesia in Total Knee Arthroplasty: A Pharmacokinetic Study to Determine Safety Following Fixed-Dose Administration.
PubMed 文献 · Reg Anesth Pain Med · 2018-01-01

前瞻性观察15例择期全膝关节置换术患者,采用300 mg罗哌卡因加5 μg/mL肾上腺素行局部浸润镇痛,测定止血带释放后24小时内总罗哌卡因血药浓度。中位峰值浓度为0.57 μg/mL(范围0.32–0.88),出现在6–24小时,所有患者均低于所引用的毒性浓度2.2 μg/mL。年龄、体重、肌酐和女性是峰值浓度的重要预测因素。

要点

  • 固定剂量300 mg罗哌卡因局部浸润镇痛后,总血药浓度峰值均低于毒性阈值2.2 μg/mL。
  • 峰值浓度出现较晚,在止血带释放后6–24小时,晚于既往神经轴或外周神经阻滞的描述。
  • 年龄、体重、肾功能和女性性别影响罗哌卡因全身浓度,计划局部浸润镇痛时应考虑。

核心结论

  • 所有患者峰值总罗哌卡因浓度低于所引用的毒性浓度2.2 μg/mL。
  • 峰值浓度出现在止血带释放后6–24小时,晚于既往神经轴或外周神经阻滞的描述。
  • 年龄、体重和肾功能对罗哌卡因全身浓度的影响应在计划局部浸润镇痛时考虑。
  • 女性性别是既往未与罗哌卡因峰值浓度关联的因素。

研究设计与样本

  • 前瞻性观察性研究,纳入15例择期全膝关节置换术患者。
  • 局部浸润镇痛采用标准技术给予300 mg罗哌卡因和5 μg/mL肾上腺素。
  • 止血带释放后24小时内特定时间点测定总罗哌卡因浓度,用液相色谱-质谱法分析。

主要发现

  • 中位峰值罗哌卡因浓度为0.57 μg/mL,范围0.32–0.88 μg/mL,出现在6–24小时。
  • 年龄(P=0.04)、体重(P=0.04)、肌酐(P=0.02)和女性性别(P=0.03)是峰值浓度的重要预测因素。
  • 年龄(P=0.02)、女性性别(P=0.01)和基线α1酸性糖蛋白浓度(P=0.03)是罗哌卡因浓度-时间曲线下面积的重要预测因素。

临床怎么用

  • 固定剂量300 mg罗哌卡因局部浸润镇痛后应关注6–24小时的峰值浓度,而非仅早期监测。
  • 计划局部浸润镇痛时应考虑年龄、体重和肾功能对罗哌卡因全身浓度的影响。
  • 女性性别与峰值浓度相关,临床中需注意该因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: The primary aim of this study was to examine the pharmacokinetics of ropivacaine in patients undergoing elective total knee arthroplasty with local infiltration analgesia as the primary analgesic method. We also sought to determine the incidence of biochemical toxicity through measurement of plasma ropivacaine concentrations over the first 24 hours postoperatively. METHODS: This was a prospective, observational study of 15 patients undergoing elective total knee arthroplasty. Local infiltration analgesia was administered by standard technique with 300 mg ropivacaine and epinephrine 5 μg/mL. Total ropivacaine concentrations were taken at specified time intervals in the 24 hours after tourniquet release and analyzed by liquid chromatography-mass spectrometry. RESULTS: Fifteen patients were enrolled into the study. The median peak ropivacaine concentration was 0.57 μg/mL, with a range of 0.32 to 0.88 μg/mL, and occurred between 6 and 24 hours. Age (P = 0.04), weight (P = 0.04), creatinine (P = 0.02), and female sex (P = 0.03) were important predictors of peak concentration. Age (P = 0.02), female sex (P = 0.01), and baseline α1 acid glycoprotein concentrations (P = 0.03) were important predictors for the area under the curve from a ropivacaine concentration versus time plot. CONCLUSIONS: The peak total ropivacaine concentration was below quoted toxic concentrations (2.2 μg/mL) in all patients. This peak occurred later than has previously been described in those undergoing neuraxial or peripheral nerve block, occurring between 6 and 24 hours. The influence of age, weight, and renal function on systemic ropivacaine concentration should be considered when planning local infiltration analgesia. Female sex is a factor that has not previously been associated with peak ropivacaine concentrations.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Miller RJ, Cameron AJ, Dimech J, et al. Plasma Ropivacaine Concentrations Following Local Infiltration Analgesia in Total Knee Arthroplasty: A Pharmacokinetic Study to Determine Safety Following Fixed-Dose Administration. Reg Anesth Pain Med. 2018. PMID: 29369957. doi:10.1097/AAP.0000000000000727

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。